Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

MR-guided focused ultrasound is a new technique that involves focusing 1024 beams of ultrasound through the skull to a focal point in the brain, very much like using the sun and a magnifying glass to burn a hole in a sheet of paper.

22 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

A researcher at The Feinstein Institute for Medical Research has discovered additional mechanical properties of articular cartilage, a protective cartilage on the ends of bones that wears down over time, resulting in the development of osteoarthritis.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

Abnormal protein translation leads to Fragile X ataxia, study finds

A bizarre twist on the usual way proteins are made may explain mysterious symptoms in the grandparents of some children with mental disabilities.

19 Apr 2013

Telemedicine house calls for Parkinson’s patients: an interview with Dr Ray Dorsey, Johns Hopkins University

Access to neurological care for Parkinson disease is currently limited by distance, disability, and the distribution of doctors.

18 Apr 2013

FDA authorizes SK Biopharmaceuticals' IND application for SKL15508 to treat CIAS

The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced today the U.S. Food and Drug Administration has authorized the Investigational New Drug application for SKL15508 to treat cognitive impairment associated with schizophrenia.

18 Apr 2013

Americans with brain diseases have more difficulty in finding a neurologist, new study reveals

Americans with brain diseases such as Alzheimer's disease, Parkinson's disease or multiple sclerosis who need to see a neurologist may face longer wait times or have more difficulty finding a neurologist, according to a new study published in the April 17, 2013, online issue of Neurology-, the medical journal of the American Academy of Neurology.

18 Apr 2013

Research suggests fainting may be genetic while certain triggers may not be inherited

New research suggests that fainting may be genetic and, in some families, only one gene may be responsible. However, a predisposition to certain triggers, such as emotional distress or the sight of blood, may not be inherited.

16 Apr 2013

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility.

16 Apr 2013

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

16 Apr 2013

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.

15 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

Gold nano-bullets to defeat cancer

Cutting edge research into an experimental therapy that deploys nano-particles of gold in the fight against cancer earned an Alberta high school student, 16, top national honours today in the 2013 "Sanofi BioGENEius Challenge Canada" (SBCC).

11 Apr 2013

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its Brio, Libra and LibraXP deep brain stimulation systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person's muscles to contract and involuntarily spasm, reducing the ability to control movement.

11 Apr 2013

Many HDLS patients still incorrectly diagnosed

The very serious hereditary disease HDLS was discovered in 1984 in Sweden. Many HDLS patients are still incorrectly diagnosed with Alzheimer's disease, MS or Parkinson's disease, but researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have now developed a more certain diagnosis method - and are seeking to find a treatment for the "unknown" neurological disorder.

11 Apr 2013

Researchers develop new imaging system for mouse brain studies

Setting a mouse free to roam might alarm most people, but not so for nuclear imaging researchers from the U.S. Department of Energy's Thomas Jefferson National Accelerator Facility, Oak Ridge National Laboratory, Johns Hopkins Medical School and the University of Maryland who have developed a new imaging system for mouse brain studies.

10 Apr 2013

Cognoptix provides update on multi-site clinical trial of SAPPHIRE II eye test

Cognoptix announced today that it has reached the halfway point in a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes.

10 Apr 2013

Weill Cornell Medical College sets up new Feil Family Brain and Mind Research Institute

Weill Cornell Medical College has established the new Feil Family Brain and Mind Research Institute, a unique, multidisciplinary translational neuroscience research hub. Named in honor of long-time benefactors Gertrude and Louis Feil, the institute was created with a generous $28 million gift from the Feil Family.

9 Apr 2013

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Abnormal protein translation leads to Fragile X ataxia, study finds

Telemedicine house calls for Parkinson’s patients: an interview with Dr Ray Dorsey, Johns Hopkins University

FDA authorizes SK Biopharmaceuticals' IND application for SKL15508 to treat CIAS

Americans with brain diseases have more difficulty in finding a neurologist, new study reveals

Research suggests fainting may be genetic while certain triggers may not be inherited

Rhythm starts RM-131 Phase 2 clinical trial for treatment of chronic constipation

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Gold nano-bullets to defeat cancer

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

Many HDLS patients still incorrectly diagnosed

Researchers develop new imaging system for mouse brain studies

Cognoptix provides update on multi-site clinical trial of SAPPHIRE II eye test

Weill Cornell Medical College sets up new Feil Family Brain and Mind Research Institute

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in